Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
Claudia MassarottiElvira SbragiaGiacomo BoffaCaterina VercelliGiovanni Bosco ZimatoreSalvatore CottoneJessica FrauAnnamaria RaiolaRiccardo VaraldoGianluigi MancardiMatilde InglesePaola AnseriniPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Data on fertility after autologous hematopoietic stem cell transplantation (aHSCT) in women with multiple sclerosis (MS) are inconclusive. This study aims to report on post-aHSCT menstrual resumption in a multi-center MS-women cohort. Out of 43 women, 30 (70%) recovered menses after a mean time of 6.8 months. Older age (odds ratio (OR) = 0.5, p < 0.0001) and previous pulsed cyclophosphamide (OR = 0.44, p = 0.005) were independently associated with a reduced menstrual recovery probability. Conditioning regimens' intensity resulted not associated with post-procedure amenorrhea. Our results highlight younger age as significantly associated with menses recovery; proper fertility counseling for MS women candidated to aHSCT both prior- and post-transplantation is therefore warranted.
Keyphrases
- multiple sclerosis
- polycystic ovary syndrome
- mass spectrometry
- ms ms
- pregnancy outcomes
- white matter
- cell therapy
- acute myeloid leukemia
- cervical cancer screening
- bone marrow
- low dose
- insulin resistance
- platelet rich plasma
- childhood cancer
- machine learning
- big data
- minimally invasive
- high intensity
- type diabetes
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- men who have sex with men
- community dwelling
- deep learning
- artificial intelligence
- hiv infected